GE Healthcare Technologies Inc (GEHC) AI Stock Analysis

• Market Cap: $34.14B
• Dividend Yield: 0.19%
• Average Volume (3M): 3.22M
• Price to Earnings (P/E): 15.3
• Beta (1Y): 1.30
• Revenue Growth: 2.30%
• EPS Growth: 41.46%
• Country: US
• Employees: 53,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 1.06
• Shares Outstanding: 456,562,040
• 10 Day Avg. Volume: 3,780,490
• 30 Day Avg. Volume: 3,219,912
• PEG Ratio: 0.41
• Price to Book (P/B): 4.22
• Price to Sales (P/S): 1.81
• P/FCF Ratio: 23.00
• Enterprise Value/Market Cap: 1.20
• Enterprise Value/Revenue: 2.06
• Enterprise Value/Gross Profit: 4.96
• Enterprise Value/Ebitda: 10.74
• 1Y Price Target: $86.71
• Price Target Upside: 17.21% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 77 Outperform
• Price Target: $84.00 ▲(13.54% Upside)

GE Healthcare Technologies Inc. presents a robust financial profile with strong profitability and strategic growth initiatives. The earnings call provided a positive outlook, supported by strategic collaborations and a strong backlog. While technical indicators suggest some short-term caution, the company's solid financial health and reasonable valuation underpin a favorable long-term investment outlook.

Positive Factors

Strategic Collaborations

Strategic collaborations and large orders enhance GE Healthcare's market position and revenue potential, supporting long-term growth.

R&D Investments

Strong R&D investments leading to successful new products bolster competitive advantage and drive sustainable revenue growth.

Acquisition of icometrix

The acquisition of icometrix enhances GE Healthcare's AI capabilities in brain imaging, strengthening its product offerings and market position.

Negative Factors

Tariff Impacts on Margins

Tariff impacts are reducing margins, which could pressure profitability and require strategic adjustments to maintain financial health.

China Market Challenges

Prolonged recovery in China poses risks to revenue growth, requiring strategic focus to mitigate regional market challenges.

Patient Care Solutions Flat Revenue

Flat revenue and declining margins in Patient Care Solutions indicate potential issues in product competitiveness or market demand.

GE Healthcare Technologies Inc Business Overview & Revenue Model

Company Description

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

How the Company Makes Money

GE Healthcare generates revenue through multiple streams, primarily by selling medical imaging equipment, patient monitoring systems, and diagnostic tools to healthcare institutions worldwide. The company also earns significant income from software solutions and services, including digital health platforms that facilitate data management and analytics for healthcare providers. Additionally, GEHC benefits from long-term service agreements and maintenance contracts, which provide ongoing revenue through repairs, upgrades, and technical support for installed equipment. Strategic partnerships with hospitals, research institutions, and technology firms further enhance its market reach and contribute to its earnings by enabling collaborative innovations and expanding its product offerings.

GE Healthcare Technologies Inc Financial Statement Overview

Summary

GE Healthcare Technologies Inc. demonstrates strong financial performance with consistent revenue growth, robust profitability margins, and prudent debt management. The balance sheet is stable with low leverage, and the cash flow statement reflects adequate liquidity and strong cash generation capabilities. While revenue growth is moderate, the overall financial health is solid.

Income Statement

GE Healthcare Technologies Inc. shows strong financial performance with consistent revenue growth, achieving a TTM revenue of $19.97 billion. Gross and net profit margins remain healthy at 41.56% and 11.23% respectively, indicating effective cost management and profitability. The EBIT and EBITDA margins of 13.82% and 18.09% further reinforce operational efficiency. The revenue growth rate from 2024 to TTM is 1.49%, demonstrating moderate upward momentum.

Balance Sheet

The balance sheet reveals a solid financial structure with a debt-to-equity ratio of 0.21, highlighting low leverage and financial stability. The equity ratio stands at 27.36%, indicating a substantial proportion of assets funded by equity. The return on equity is robust at 23.07%, showcasing effective utilization of shareholders' equity to generate profits. Overall, the balance sheet reflects a strong financial position with manageable debt levels.

Cash Flow

The cash flow statement indicates healthy liquidity with a free cash flow of $1.22 billion in TTM. The free cash flow to net income ratio is 0.54, and the operating cash flow to net income ratio is 0.74, demonstrating efficient cash generation relative to earnings. However, there is a decline in free cash flow from the previous year, indicating potential areas for improvement in cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	19.96B	19.67B	19.55B	18.34B	17.59B	17.16B
Gross Profit	8.30B	8.21B	7.92B	7.18B	7.17B	6.77B
EBITDA	3.83B	3.67B	3.51B	3.17B	3.54B	3.41B
Net Income	2.24B	1.99B	1.57B	1.92B	2.25B	13.85B
Balance Sheet
Total Assets	35.50B	33.09B	32.45B	27.54B	26.31B	24.23B
Cash, Cash Equivalents and Short-Term Investments	3.76B	2.89B	2.50B	1.45B	556.00M	1.01B
Total Debt	10.72B	9.38B	9.86B	8.63B	437.00M	468.00M
Total Liabilities	25.55B	24.44B	25.14B	17.95B	9.41B	9.25B
Stockholders Equity	9.71B	8.45B	7.13B	9.36B	16.66B	14.73B
Cash Flow
Free Cash Flow	1.56B	1.55B	1.71B	1.80B	1.36B	1.43B
Operating Cash Flow	2.00B	1.95B	2.10B	2.11B	1.61B	1.69B
Investing Cash Flow	-1.01B	-914.00M	-558.00M	-398.00M	-1.76B	19.99B
Financing Cash Flow	712.00M	-573.00M	-478.00M	-822.00M	-263.00M	-21.54B

GE Healthcare Technologies Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 73.98
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GEHC, the sentiment is Negative. The current price of 73.98 is below the 20-day moving average (MA) of 75.21, below the 50-day MA of 74.47, and below the 200-day MA of 76.87, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 38.98 is Neutral, neither overbought nor oversold. The STOCH value of 14.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GEHC.

GE Healthcare Technologies Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DOCS	80 Outperform	13.91B	63.85	22.93%	―	19.45%	46.46%
HQY	79 Outperform	8.12B	58.21	6.79%	―	15.45%	37.72%
GEHC	77 Outperform	$34.14B	15.31	25.60%	0.19%	2.30%	41.46%
VEEV	77 Outperform	45.56B	57.43	12.20%	―	15.33%	30.51%
HNGE	60 Neutral	4.25B	-9.38	-2.86%	―	43.35%	-430.79%
TEM	59 Neutral	13.76B	-65.30	-64.52%	―	59.84%	76.46%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

GE Healthcare Technologies Inc Corporate Events

GE Healthcare Board Member Resigns Abruptly

On July 23, 2025, Lloyd W. Howell, Jr. resigned from GE Healthcare Technologies Inc.’s Board of Directors, effective immediately. His departure was not due to any disagreement with the company’s operations, policies, or practices.

GE Healthcare Issues $1.5 Billion in Senior Notes

On June 9, 2025, GE Healthcare Technologies Inc. issued $1.5 billion in senior notes, divided into $650 million due in 2031 and $850 million due in 2035. These senior unsecured notes are part of the company’s strategy to manage its debt portfolio and maintain its financial flexibility, potentially impacting its market positioning and stakeholder interests.